Cowen & Co. Keeps a Buy Rating on Supernus Pharmaceuticals (SUPN)


In a report released yesterday, Ken Cacciatore from Cowen & Co. maintained a Buy rating on Supernus Pharmaceuticals (SUPN), with a price target of $55. The company’s shares closed yesterday at $47.42.

According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 1.1% and a 43.9% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Liquidia Technologies Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.

Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $59, a 24.4% upside from current levels. In a report issued on November 15, Mizuho Securities also reiterated a Buy rating on the stock with a $61 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $61.25 and a one-year low of $34.90. Currently, Supernus Pharmaceuticals has an average volume of 561.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts